Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 477

1.

A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma.

Goldman-Mazur S, Jurczyszyn A, Castillo JJ, Waszczuk-Gajda A, GrzĄŚko N, Radocha J, Bittrich M, Kortüm KM, Gozzetti A, Usnarska-Zubkiewicz L, Valls JD, Jayabalan DS, Niesvizky R, Kelman J, Coriu D, Rosiñol L, Szukalski Ł, González-Calle V, Mateos MV, Jamroziak K, Hus I, Avivi I, Cohen Y, Suska A, Chappell A, Madduri D, Chhabra S, Kleman A, Hari P, Delforge M, Robak P, Gentile M, Kozłowska I, Goldberg SL, Czepiel J, Silbermann R, Olszewski AJ, Barth P, Mikala G, Chim CS, Długosz-Danecka M, Grosicki S, Vesole DH.

Am J Hematol. 2020 Feb 18. doi: 10.1002/ajh.25758. [Epub ahead of print]

PMID:
32072687
2.

Comparison of efficacy from two different dosing regimens of bortezomib: an exposure-response analysis.

Parasrampuria DA, He J, Zhang L, Muresan B, Hu P, Nemat S, Hashim M, Lam A, Appiani C, Cavo M, Dimopoulos MA, San-Miguel J, Mateos MV.

Br J Haematol. 2020 Feb 18. doi: 10.1111/bjh.16446. [Epub ahead of print]

PMID:
32068255
3.

Molecular profiling of immunoglobulin heavy-chain gene rearrangements unveils new potential prognostic markers for multiple myeloma patients.

Medina A, Jiménez C, Sarasquete ME, González M, Chillón MC, Balanzategui A, Prieto-Conde I, García-Álvarez M, Puig N, González-Calle V, Alcoceba M, Cuenca I, Barrio S, Escalante F, Gutiérrez NC, Gironella M, Hernández MT, Sureda A, Oriol A, Bladé J, Lahuerta JJ, San Miguel JF, Mateos MV, Martínez-López J, Calasanz MJ, García-Sanz R.

Blood Cancer J. 2020 Feb 6;10(2):14. doi: 10.1038/s41408-020-0283-8.

4.

Response to Everolimus of a Progressive Plexiform Neurofibroma in NF type 1.

Mateos ME, López-Laso E, Vicente J, Ortega R, Vázquez F, Pérez-Navero JL.

Pediatr Int. 2020 Feb 6. doi: 10.1111/ped.14183. [Epub ahead of print]

PMID:
32027426
5.

Therapeutic Drug Monitoring of Antifungal Drugs: Another Tool to Improve Patient Outcome?

Vena A, Muñoz P, Mateos M, Guinea J, Galar A, Pea F, Alvarez-Uria A, Escribano P, Bouza E.

Infect Dis Ther. 2020 Feb 5. doi: 10.1007/s40121-020-00280-y. [Epub ahead of print]

PMID:
32026399
6.

First-in-Human Phase 1 Study of ABBV-838, an Antibody-Drug Conjugate Targeting SLAMF7/CS1 in Patients With Relapsed and Refractory Multiple Myeloma.

Vij R, Nath R, Afar DEH, Mateos MV, Berdeja JG, Raab MS, Guenther A, Martinez-Lopez J, Jakubowiak AJ, Leleu X, Weisel K, Wong S, Gulbranson S, Sheridan JP, Reddy A, Paiva B, Singhal A, San-Miguel JF, Moreau P.

Clin Cancer Res. 2020 Jan 22. pii: clincanres.1431.2019. doi: 10.1158/1078-0432.CCR-19-1431. [Epub ahead of print]

PMID:
31969330
7.

EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies.

Kiesewetter B, Cherny NI, Boissel N, Cerisoli F, Dafni U, de Vries EGE, Ghia P, Gökbuget N, González-Calle V, Huntly B, Jäger U, Latino NJ, Douillard JY, Malcovati L, Mateos MV, Ossenkoppele GJ, Porkka K, Raderer M M.D, Ribera JM, Scarfò L, Wester R, Zygoura P, Sonneveld P.

ESMO Open. 2020 Jan;5(1). pii: e000611. doi: 10.1136/esmoopen-2019-000611.

8.

A new regulatory mechanism of protein phosphatase 2A activity via SET in acute myeloid leukemia.

Arriazu E, Vicente C, Pippa R, Peris I, Martínez-Balsalobre E, García-Ramírez P, Marcotegui N, Igea A, Alignani D, Rifón J, Mateos MC, Cayuela ML, Nebreda AR, Odero MD.

Blood Cancer J. 2020 Jan 8;10(1):3. doi: 10.1038/s41408-019-0270-0.

9.

Lipid Signaling in Retinal Pigment Epithelium Cells Exposed to Inflammatory and Oxidative Stress Conditions. Molecular Mechanisms Underlying Degenerative Retinal Diseases.

Bermúdez V, Tenconi PE, Giusto NM, Mateos MV.

Adv Exp Med Biol. 2019;1185:289-293. doi: 10.1007/978-3-030-27378-1_47.

PMID:
31884626
10.

The Australia and New Zealand Cardio-Oncology Registry (ACOR): evaluation of chemotherapy-related cardiotoxicity in a national cohort of paediatric cancer patients.

Lapirow D, La Gerche A, Toro C, Masango E, Costello B, Porello E, Ludlow L, Marshall G, Trahair T, Mateos M, Lewin J, Byrne J, Boutros R, Manudhane R, Heath J, Ayer J, Gabriel M, Walwyn T, Saundankar J, Forsey J, Le H, Mason K, Celermajer D, Downie P, Walker R, Holland L, Martin M, McLeman L, Diamond Y, Marcocci M, Donath S, Cheung M, Elliott DA, Conyers R.

Intern Med J. 2019 Dec 16. doi: 10.1111/imj.14719. [Epub ahead of print]

PMID:
31841257
11.

Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial.

Mateos MV, Cavo M, Blade J, Dimopoulos MA, Suzuki K, Jakubowiak A, Knop S, Doyen C, Lucio P, Nagy Z, Pour L, Cook M, Grosicki S, Crepaldi A, Liberati AM, Campbell P, Shelekhova T, Yoon SS, Iosava G, Fujisaki T, Garg M, Krevvata M, Chen Y, Wang J, Kudva A, Ukropec J, Wroblewski S, Qi M, Kobos R, San-Miguel J.

Lancet. 2020 Jan 11;395(10218):132-141. doi: 10.1016/S0140-6736(19)32956-3. Epub 2019 Dec 10.

PMID:
31836199
12.

Minimal Residual Disease Status as a Surrogate Endpoint for Progression-free Survival in Newly Diagnosed Multiple Myeloma Studies: A Meta-analysis.

Avet-Loiseau H, Ludwig H, Landgren O, Paiva B, Morris C, Yang H, Zhou K, Ro S, Mateos MV.

Clin Lymphoma Myeloma Leuk. 2020 Jan;20(1):e30-e37. doi: 10.1016/j.clml.2019.09.622. Epub 2019 Oct 9.

PMID:
31780415
13.

Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma.

Paiva B, Puig N, Cedena MT, Rosiñol L, Cordón L, Vidriales MB, Burgos L, Flores-Montero J, Sanoja-Flores L, Lopez-Anglada L, Maldonado R, de la Cruz J, Gutierrez NC, Calasanz MJ, Martin-Ramos ML, Garcia-Sanz R, Martinez-Lopez J, Oriol A, Blanchard MJ, Rios R, Martin J, Martinez-Martinez R, Sureda A, Hernandez MT, de la Rubia J, Krsnik I, Moraleda JM, Palomera L, Bargay J, Van Dongen JJM, Orfao A, Mateos MV, Blade J, San-Miguel JF, Lahuerta JJ; GEM (Grupo Español de Mieloma)/PETHEMA (Programa Para el Estudio de la Terapéutica en Hemopatías Malignas) Cooperative Study Group.

J Clin Oncol. 2019 Nov 26:JCO1901231. doi: 10.1200/JCO.19.01231. [Epub ahead of print]

PMID:
31770060
14.

Transcriptome analysis reveals significant differences between primary plasma cell leukemia and multiple myeloma even when sharing a similar genetic background.

Rojas EA, Corchete LA, Mateos MV, García-Sanz R, Misiewicz-Krzeminska I, Gutiérrez NC.

Blood Cancer J. 2019 Nov 20;9(12):90. doi: 10.1038/s41408-019-0253-1.

15.

A novel voxel-based method to estimate cortical sulci width and its application to compare patients with Alzheimer's disease to controls.

Mateos MJ, Gastelum-Strozzi A, Barrios FA, Bribiesca E, Alcauter S, Marquez-Flores JA.

Neuroimage. 2020 Feb 15;207:116343. doi: 10.1016/j.neuroimage.2019.116343. Epub 2019 Nov 14.

16.

Drug-induced Thrombotic Microangiopathy During Maintenance Treatment in a Patient With Multiple Myeloma.

Higuero Saavedra V, González-Calle V, Sobejano E, Sebastiá J, Cabrero M, Bastida JM, Puig N, Ocio EM, Mateos MV.

Hemasphere. 2019 Jun 4;3(3):e192. doi: 10.1097/HS9.0000000000000192. eCollection 2019 Jun. No abstract available.

17.

Insights on Multiple Myeloma Treatment Strategies.

Mateos MV, Ludwig H, Bazarbachi A, Beksac M, Bladé J, Boccadoro M, Cavo M, Delforge M, Dimopoulos MA, Facon T, Geraldes C, Goldschmidt H, Hájek R, Hansson M, Jamroziak K, Leiba M, Masszi T, Mendeleeva L, O'Dwyer M, Plesner T, San-Miguel JF, Straka C, van de Donk NWCJ, Yong K, Zver S, Moreau P, Sonneveld P.

Hemasphere. 2018 Dec 27;3(1):e163. doi: 10.1097/HS9.0000000000000163. eCollection 2019 Feb. Review.

18.

A new species of the live-bearing fish genus Poeciliopsis from northern Mexico (Cyprinodontiformes, Poeciliidae).

Conway KW, Mateos M, Vrijenhoek RC.

Zookeys. 2019 Oct 28;883:91-118. doi: 10.3897/zookeys.883.37586. eCollection 2019.

19.

Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy.

Sanoja-Flores L, Flores-Montero J, Puig N, Contreras-Sanfeliciano T, Pontes R, Corral-Mateos A, García-Sánchez O, Díez-Campelo M, Pessoa de Magalhães RJ, García-Martín L, Alonso-Alonso JM, García-Mateo A, Aguilar-Franco C, Labrador J, Barez-García A, Maiolino A, Paiva B, San Miguel J, Sobral da Costa E, González M, Mateos MV, Durie B, van Dongen JJM, Orfao A.

Blood. 2019 Dec 12;134(24):2218-2222. doi: 10.1182/blood.2019002610. No abstract available.

20.

The effects of different schedules of bortezomib, melphalan, and prednisone for patients with newly diagnosed multiple myeloma who are transplant ineligible: a matching-adjusted indirect comparison.

Mateos MV, San-Miguel J, Goldschmidt H, Sonneveld P, Dimopoulos MA, Heeg B, Hashim M, Deraedt W, Hu P, Lam A, He J.

Leuk Lymphoma. 2020 Mar;61(3):680-690. doi: 10.1080/10428194.2019.1675881. Epub 2019 Nov 5.

PMID:
31686561
21.

A matching-adjusted indirect treatment comparison (MAIC) of daratumumab-bortezomib-melphalan-prednisone (D-VMP) versus lenalidomide-dexamethasone continuous (Rd continuous), lenalidomide-dexamethasone 18 months (Rd 18), and melphalan-prednisone-thalidomide (MPT).

Dimopoulos MA, Cavo M, Mateos MV, Facon T, Heeg B, van Beekhuizen S, Gebregergish SB, Nair S, Pisini M, Lam A, Slavcev M.

Leuk Lymphoma. 2020 Mar;61(3):714-720. doi: 10.1080/10428194.2019.1682571. Epub 2019 Nov 5.

PMID:
31686559
22.

Population genetics and historical demographic inferences of the blue crab Callinectes sapidus in the US based on microsatellites.

Macedo D, Caballero I, Mateos M, Leblois R, McCay S, Hurtado LA.

PeerJ. 2019 Oct 14;7:e7780. doi: 10.7717/peerj.7780. eCollection 2019.

23.

A novel FTY720 analogue targets SET-PP2A interaction and inhibits growth of acute myeloid leukemia cells without inducing cardiac toxicity.

Vicente C, Arriazu E, Martínez-Balsalobre E, Peris I, Marcotegui N, García-Ramírez P, Pippa R, Rabal O, Oyarzábal J, Guruceaga E, Prósper F, Mateos MC, Cayuela ML, Odero MD.

Cancer Lett. 2020 Jan 1;468:1-13. doi: 10.1016/j.canlet.2019.10.007. Epub 2019 Oct 5.

PMID:
31593801
24.

Efficacy of bortezomib to intensify the conditioning regimen and the graft-versus-host disease prophylaxis for high-risk myeloma patients undergoing transplantation.

Caballero-Velázquez T, Calderón-Cabrera C, López-Corral L, Puig N, Marquez-Malaver F, Pérez-López E, García-Calderón C, Rosso-Fernández CM, Caballero Barrigón D, Martín J, Mateos MV, San Miguel J, Pérez-Simón JA; European Myeloma Network.

Bone Marrow Transplant. 2020 Feb;55(2):419-430. doi: 10.1038/s41409-019-0670-6. Epub 2019 Sep 24.

PMID:
31551517
25.

Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma.

Rosiñol L, Oriol A, Rios R, Sureda A, Blanchard MJ, Hernández MT, Martínez-Martínez R, Moraleda JM, Jarque I, Bargay J, Gironella M, de Arriba F, Palomera L, González-Montes Y, Martí JM, Krsnik I, Arguiñano JM, González ME, González AP, Casado LF, López-Anglada L, Paiva B, Mateos MV, San Miguel JF, Lahuerta JJ, Bladé J.

Blood. 2019 Oct 17;134(16):1337-1345. doi: 10.1182/blood.2019000241.

26.

Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network.

Moreau P, Sonneveld P, Boccadoro M, Cook G, Mateos MV, Nahi H, Goldschmidt H, Dimopoulos MA, Lucio P, Bladé J, Delforge M, Hajek R, Ludwig H, Facon T, Miguel JFS, Einsele H.

Haematologica. 2019 Dec;104(12):2358-2360. doi: 10.3324/haematol.2019.224204. Epub 2019 Aug 22.

27.

Dementia-related neuropsychiatric symptoms: inequalities in pharmacological treatment and institutionalization.

Mar J, Arrospide A, Soto-Gordoa M, Iruin Á, Tainta M, Gabilondo A, Mar-Barrutia L, Calvo M, Mateos M, Ibarrondo O.

Neuropsychiatr Dis Treat. 2019 Jul 17;15:2027-2034. doi: 10.2147/NDT.S209008. eCollection 2019.

28.

Lipopolysaccharide-Induced Autophagy Mediates Retinal Pigment Epithelium Cells Survival. Modulation by the Phospholipase D Pathway.

Bermúdez V, Tenconi PE, Giusto NM, Mateos MV.

Front Cell Neurosci. 2019 Apr 24;13:154. doi: 10.3389/fncel.2019.00154. eCollection 2019.

29.

Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial.

Mateos MV, Blacklock H, Schjesvold F, Oriol A, Simpson D, George A, Goldschmidt H, Larocca A, Chanan-Khan A, Sherbenou D, Avivi I, Benyamini N, Iida S, Matsumoto M, Suzuki K, Ribrag V, Usmani SZ, Jagannath S, Ocio EM, Rodriguez-Otero P, San Miguel J, Kher U, Farooqui M, Liao J, Marinello P, Lonial S; KEYNOTE-183 Investigators.

Lancet Haematol. 2019 Sep;6(9):e459-e469. doi: 10.1016/S2352-3026(19)30110-3. Epub 2019 Jul 18.

PMID:
31327687
30.

Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma.

Algarín EM, Díaz-Tejedor A, Mogollón P, Hernández-García S, Corchete LA, San-Segundo L, Martín-Sánchez M, González-Méndez L, Schoumacher M, Banquet S, Kraus-Berthier L, Kloos I, Derreal A, Halilovic E, Maacke H, Gutiérrez NC, Mateos MV, Paíno T, Garayoa M, Ocio EM.

Haematologica. 2019 Jul 18. pii: haematol.2018.212308. doi: 10.3324/haematol.2018.212308. [Epub ahead of print]

31.

Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma.

Usmani SZ, Nahi H, Mateos MV, van de Donk NWCJ, Chari A, Kaufman JL, Moreau P, Oriol A, Plesner T, Benboubker L, Hellemans P, Masterson T, Clemens PL, Luo M, Liu K, San-Miguel J.

Blood. 2019 Aug 22;134(8):668-677. doi: 10.1182/blood.2019000667. Epub 2019 Jul 3.

32.

Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma.

Spicka I, Ocio EM, Oakervee HE, Greil R, Banh RH, Huang SY, D'Rozario JM, Dimopoulos MA, Martínez S, Extremera S, Kahatt C, Alfaro V, Carella AM, Meuleman N, Hájek R, Symeonidis A, Min CK, Cannell P, Ludwig H, Sonneveld P, Mateos MV.

Ann Hematol. 2019 Sep;98(9):2139-2150. doi: 10.1007/s00277-019-03739-2. Epub 2019 Jun 25.

33.

Effect of heritable symbionts on maternally-derived embryo transcripts.

Mateos M, Silva NO, Ramirez P, Higareda-Alvear VM, Aramayo R, Erickson JW.

Sci Rep. 2019 Jun 20;9(1):8847. doi: 10.1038/s41598-019-45371-0.

34.

Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies.

Mateos MV, Spencer A, Nooka AK, Pour L, Weisel K, Cavo M, Laubach JP, Cook G, Iida S, Benboubker L, Usmani SZ, Yoon SS, Bahlis NJ, Chiu C, Ukropec J, Schecter JM, Qin X, O'Rourke L, Dimopoulos MA.

Haematologica. 2020 Jan 31;105(2):468-477. doi: 10.3324/haematol.2019.217448. Print 2020.

35.

International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders.

Hillengass J, Usmani S, Rajkumar SV, Durie BGM, Mateos MV, Lonial S, Joao C, Anderson KC, García-Sanz R, Riva E, Du J, van de Donk N, Berdeja JG, Terpos E, Zamagni E, Kyle RA, San Miguel J, Goldschmidt H, Giralt S, Kumar S, Raje N, Ludwig H, Ocio E, Schots R, Einsele H, Schjesvold F, Chen WM, Abildgaard N, Lipe BC, Dytfeld D, Wirk BM, Drake M, Cavo M, Lahuerta JJ, Lentzsch S.

Lancet Oncol. 2019 Jun;20(6):e302-e312. doi: 10.1016/S1470-2045(19)30309-2. Review. Erratum in: Lancet Oncol. 2019 Jul;20(7):e346.

PMID:
31162104
36.

Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma.

Chari A, Martinez-Lopez J, Mateos MV, Bladé J, Benboubker L, Oriol A, Arnulf B, Rodriguez-Otero P, Pineiro L, Jakubowiak A, de Boer C, Wang J, Clemens PL, Ukropec J, Schecter J, Lonial S, Moreau P.

Blood. 2019 Aug 1;134(5):421-431. doi: 10.1182/blood.2019000722. Epub 2019 May 21.

37.

Understanding mortality in multiple myeloma: Findings of a European retrospective chart review.

Mohty M, Cavo M, Fink L, Gonzalez-McQuire S, Leleu H, Mateos MV, Raab MS, Schoen P, Yong K.

Eur J Haematol. 2019 Aug;103(2):107-115. doi: 10.1111/ejh.13264. Epub 2019 Jun 18.

38.

Pembrolizumab combined with lenalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE-023 study.

Mateos MV, Orlowski RZ, Ocio EM, Rodríguez-Otero P, Reece D, Moreau P, Munshi N, Avigan DE, Siegel DS, Ghori R, Farooqui MZH, Marinello P, San-Miguel J.

Br J Haematol. 2019 Sep;186(5):e117-e121. doi: 10.1111/bjh.15946. Epub 2019 May 15. No abstract available.

PMID:
31090915
39.

High glucose-induced phospholipase D activity in retinal pigment epithelium cells: New insights into the molecular mechanisms of diabetic retinopathy.

Tenconi PE, Bermúdez V, Oresti GM, Giusto NM, Salvador GA, Mateos MV.

Exp Eye Res. 2019 Jul;184:243-257. doi: 10.1016/j.exer.2019.04.028. Epub 2019 May 3.

PMID:
31059692
40.

Response to Novel Drugs before and after Allogeneic Stem Cell Transplantation in Patients with Relapsed Multiple Myeloma.

López-Corral L, Caballero-Velázquez T, López-Godino O, Rosiñol L, Pérez-Vicente S, Fernandez-Avilés F, Krsnik I, Morillo D, Heras I, Morgades M, Rifon JJ, Sampol A, Iniesta F, Ocio EM, Martin J, Rovira M, Cabero M, Castilla-Llorente C, Ribera JM, Torres-Juan M, Moraleda JM, Martinez C, Vázquez A, Gutierrez G, Caballero D, San Miguel JF, Mateos MV, Pérez-Simón JA.

Biol Blood Marrow Transplant. 2019 Sep;25(9):1703-1712. doi: 10.1016/j.bbmt.2019.04.026. Epub 2019 May 3.

PMID:
31054983
41.

Risk factors for symptomatic venous thromboembolism during therapy for childhood acute lymphoblastic leukemia.

Mateos MK, Trahair TN, Mayoh C, Barbaro PM, Sutton R, Revesz T, Barbaric D, Giles JE, Alvaro F, Mechinaud F, Catchpoole D, Kotecha RS, Dalla-Pozza L, Quinn MCJ, MacGregor S, Chenevix-Trench G, Marshall GM.

Thromb Res. 2019 Jun;178:132-138. doi: 10.1016/j.thromres.2019.04.011. Epub 2019 Apr 11.

PMID:
31030032
42.

Role of urine immunofixation in the complete response assessment of MM patients other than light-chain-only disease.

Lahuerta JJ, Jiménez-Ubieto A, Paiva B, Martínez-López J, González-Medina J, López-Anglada L, Cedena MT, Puig N, Oriol A, Blanchard MJ, Ríos R, Martin J, Martínez R, Sureda A, Hernández MT, de la Rubia J, Krsnik I, Cabañas V, Palomera L, Bargay J, Mateos MV, Rosiñol L, San Miguel JF, Blade J.

Blood. 2019 Jun 20;133(25):2664-2668. doi: 10.1182/blood.2019000671. Epub 2019 Apr 22.

PMID:
31010846
43.

Daratumumab is a safe and effective rescue therapy for multiple myeloma patients who relapse after allo-HSCT.

Gonzalez-Rodriguez AP, Lopez-Corral L, Fajardo DFM, Gonzalez-Huerta AJ, Palomo P, Bermudez A, Ripa TZ, Santos-Diaz P, Gonzalez-Muñiz S, Zanabilli J, Ubieto AJ, de Arriba F, Arnao-Herraiz M, Sordo-Bahamonde C, López-Soto A, Gonzalez S, Rosiñol L, Mateos MV.

Bone Marrow Transplant. 2020 Feb;55(2):461-463. doi: 10.1038/s41409-019-0525-1. Epub 2019 Apr 15. No abstract available.

PMID:
30988379
44.

Improving the conditioning regimen in multiple myeloma.

Mateos MV, González-Calle V.

Lancet Haematol. 2019 May;6(5):e234-e235. doi: 10.1016/S2352-3026(19)30028-6. Epub 2019 Mar 22. No abstract available.

PMID:
30910540
45.

Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide.

Moreau P, Zamagni E, Mateos MV.

Blood Cancer J. 2019 Mar 20;9(4):38. doi: 10.1038/s41408-019-0200-1.

46.

Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature.

Rodríguez-Otero P, Mateos MV, Martínez-López J, Hernández MT, Ocio EM, Rosiñol L, Martínez R, Teruel AI, Gutiérrez NC, Bargay J, Bengoechea E, González Y, de Oteyza JP, Gironella M, Nuñez-Córdoba JM, Encinas C, Martín J, Cabrera C, Palomera L, de Arriba F, Cedena MT, Puig N, Oriol A, Paiva B, Bladé J, Lahuerta JJ, San Miguel JF.

Blood Cancer J. 2019 Mar 18;9(4):36. doi: 10.1038/s41408-019-0176-x.

47.

A multilocus phylogeny of the fish genus Poeciliopsis: Solving taxonomic uncertainties and preliminary evidence of reticulation.

Mateos M, Domínguez-Domínguez O, Varela-Romero A.

Ecol Evol. 2019 Jan 25;9(4):1845-1857. doi: 10.1002/ece3.4874. eCollection 2019 Feb.

48.

Correction: Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability role.

Rodríguez-Otero P, Mateos MV, Martínez-López J, Martín-Calvo N, Hernández MT, Ocio EM, Rosiñol L, Martínez R, Teruel AI, Gutiérrez NC, Bargay J, Bengoechea E, González Y, de Oteyza JP, Gironella M, Encinas C, Martín J, Cabrera C, Palomera L, de Arriba F, Cedena MT, Paiva B, Puig N, Oriol A, Bladé J, Lahuerta JJ, Miguel JFS.

Leukemia. 2019 Apr;33(4):1056. doi: 10.1038/s41375-019-0408-x.

PMID:
30846864
49.

Correction: Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond.

Chim CS, Kumar SK, Orlowski RZ, Cook G, Richardson PG, Gertz MA, Giralt S, Mateos MV, Leleu X, Anderson KC.

Leukemia. 2019 Apr;33(4):1058-1059. doi: 10.1038/s41375-019-0410-3.

50.

Management of cardiovascular risk in patients with multiple myeloma.

Plummer C, Driessen C, Szabo Z, Mateos MV.

Blood Cancer J. 2019 Feb 26;9(3):26. doi: 10.1038/s41408-019-0183-y. Review.

Supplemental Content

Loading ...
Support Center